
Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, and a panel of pharmacists explore pharmacist roles in myelofibrosis care, treatment challenges, patient outcomes, and pharmacist responsibilities within interdisciplinary teams.

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, and a panel of pharmacists explore pharmacist roles in myelofibrosis care, treatment challenges, patient outcomes, and pharmacist responsibilities within interdisciplinary teams.

Experts discuss the ramifications of red blood cell transfusion shortages on myelofibrosis patient management and delve into the scarcity’s effects, patient prioritization, and the struggle for consistency in care amid supply challenges.

Pharmacists discuss the impact and alternatives amid red blood cell shortages in myelofibrosis treatment, highlighting challenges, patient outcomes, quality of life issues, and health care cost implications.

Pharmacists analyze the role of momelotinib in treating anemia in myelofibrosis, exploring its place in practice and impact on patient care amid emerging therapies.

James Davis, PharmD, BCOP, discusses momelotinib usage and highlights emerging therapies revolutionizing myelofibrosis treatment paradigms.

Pharmacists discuss challenges in transitioning myelofibrosis patients between inpatient and outpatient care settings, emphasizing medication reconciliation and seamless inter-team communication.

Experts discuss obstacles faced while transitioning myelofibrosis patients from inpatient to outpatient care, emphasizing communication, access to medication, and the need for standardized medication reconciliation protocols.

Robert Mancini, PharmD, and Victoria Nachar, PharmD, discuss strategies and resources for smooth inpatient to outpatient transitions in myelofibrosis care, highlighting medication reconciliation, financial assistance, and the need for dedicated support staff.

Pharmacists discuss tailored patient education approaches, emphasizing key medication details, side effects, and financial aspects critical for myelofibrosis care, optimizing adherence and healthcare outcomes.

Shawn Griffin, PharmD, BCOP, reviews strategies to tackle socioeconomic challenges in myelofibrosis treatment, covering costs, transportation, language barriers, cultural sensitivity, and patient communication.

Experts discuss patient advocacy, empowering patients in accessing treatments, educating them about health care systems, and collaborating with health care providers for better myelofibrosis management.

Pharmacists discuss tailoring myelofibrosis treatments to individual patient needs, focusing on symptom management, preferences, and challenges in care team collaboration.

Pharmacists discuss emerging therapies, challenges, and pharmacists’ vital role in myelofibrosis patient care, emphasizing disease-modifying agents and care team collaboration.